Evaluation of the effect of intracameral cefuroxime on macular and subfoveal choroidal thickness and macular sensitivity in diabetic patients after cataract surgery

Abstract

To evaluate the macular and subfoveal choroidal thickness variation and macular sensitivity changes in diabetic patients after intracameral cefuroxime in cataract surgery. Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai, China. Prospective case series. Diabetic patients with visually significant cataract were divided into a treatment group, which received an intracameral injection of 1mg/0.1mL cefuroxime, and a control group, which received an equal volume of 0.9% saline solution. The macular thickness and subfoveal choroidal thickness were measured by optical coherence tomography. The macular sensitivity was assessed by microperimetry using the MP-1. The study comprised 46 eyes of 38 patients. The macular thickness increased significantly both in the treatment group (P<.01) and the control group (P<.05) postoperatively. The mean variation was 8.27±μm 3.22 (SD) in the treatment eyes and 11.38±7.75μm in the control eyes. The mean preoperative subfoveal choroidal thickness was 262.86±37.02μm and 279.70±54.68μm, respectively (P=.497). No statistical difference was found in the macular thickness variation (P=.338) orsubfoveal choroidal thickness variation (P=.491) between the 2 groups. For macular sensitivity, there was no significant differencein the variation between the treatment group and the control group (6.05±2.37dB versus 5.52±4.17dB) (P=.772). Intracameral cefuroxime did not significantly influence the thickening of macula or the subfoveal choroidal thickness in diabetic patients after uneventful cataract surgery. The functional improvement in macular sensitivity was also not affected.